{"url_path":"/sec/amph/8-k/2026-06-03/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 ****Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1297184/0001297184-26-000038-index.html","accession_number":"0001297184-26-000038","cik":"0001297184","ticker":"AMPH","issuer_name":"Amphastar Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1297184/0001297184-26-000038-index.html","primary_entity_key":"0001297184","primary_entity_name":"Amphastar Pharmaceuticals, Inc."},"word_count":517,"has_tables":true,"body_markdown":"**ITEM 5.07.****Submission of Matters to a Vote of Security Holders.**\n\n** **\n\nThe stockholders of the Company voted on the following items at the Annual Meeting, each of which is described in more detail in the Company’s definitive proxy statement filed with the SEC on April 13, 2026:\n\n1.To elect three Class I directors to serve until the Company’s 2029 annual meeting of stockholders and until each such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal;\n\n2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026;\n\n3.To approve, on an advisory basis, the compensation of the Company’s named executive officers; and\n\n4.To approve, on an advisory basis, the frequency of future stockholder advisory votes on the Company’s named executive officer compensation.\n\n​\n\nThe voting results for the proposals are detailed below.\n\n​\n\n1. Election of Directors\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Nominee**\n\n**For**\n\n**Against**\n\n**Abstained**\n\n**Broker Non-votes**\n\nDavid Gaugh\n\n35,242,863\n\n209,084\n\n25,045\n\n4,439,978\n\nWilliam J. Peters\n\n23,652,131\n\n11,785,772\n\n39,089\n\n4,439,978\n\nJacob Liawatidewi\n\n23,224,791\n\n12,212,988\n\n39,213\n\n4,439,978\n\n​\n\nEach director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director’s earlier death, resignation or removal.\n\n​\n\n2. Ratification of Appointment of Independent Registered Public Accounting Firm\n\n​\n\n​\n\n**For**\n\n**Against**\n\n**Abstained**\n\n**Broker Non-votes**\n\n39,179,786\n\n684,828\n\n52,356\n\nN/A\n\n​\n\nThe stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\n​\n\n3. Advisory Vote on the Compensation of our Named Executive Officers\n\n​\n\n​\n\n**For**\n\n**Against**\n\n**Abstained**\n\n**Broker Non-votes**\n\n32,585,908\n\n2,779,281\n\n111,803\n\n4,439,978\n\n​\n\nThe stockholders approved, on a non-binding basis, the compensation of the Company’s named executive officers.\n\n​\n\n4. Advisory Vote on the Frequency of Future Stockholder Advisory Votes on Named Executive Officer Compensation\n\n​\n\n​\n\n​\n\n**1 Year**\n\n**2 Years**\n\n**3 Years**\n\n**Abstained**\n\n**Broker Non-votes**\n\n33,816,071\n\n12,329\n\n1,624,016\n\n24,576\n\n4,439,978\n\n​\n\nThe stockholders approved, on a non-binding advisory basis, that they were in favor of one year as the frequency of holding stockholder advisory votes on the compensation of the Company’s named executive officers. In accordance with the voting results for this proposal, the board of directors of the Company has determined that the Company will hold future stockholder advisory votes on the compensation of the Company’s named executive officers every year. The next required advisory vote on the frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers will take place no later than at the Company’s 2032 annual meeting of stockholders.\n\n​\n\n​\n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n​\n\n​\n\n​\n\n \n\nAMPHASTAR PHARMACEUTICALS, INC.\n\nDate: June 3, 2026\n\n \n\n​\n\nBy: /s/ William J. Peters\n\n \n\n \n\nWilliam J. Peters\n\n \n\nChief Financial Officer and Executive Vice President\n\n \n\n​\n\n​\n\n​\n\n​\n\n​"}